MEL 80 Hyperopic LASIK Treatment
DeviceTreatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
NCT Number: NCT00762281
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of hyperopia, when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Not applicable
US Navy Refractive Surgery Center, San Diego, California, United States
LASIK has become one of the most common refractive eye procedures performed in the country. In the hyperopia procedure, a steepening occurs on the corneal surface, rather than the flattening procedure (myopic treatment). The surgeon will produce a standard keratomileusis flap using a microkeratome, exposing the corneal stroma. Recontouring under the flap is then accomplished by the removal of tissue from the stroma with the laser. This recontouring results in an altering of effective lens power of the central cornea, measured in diopters (D). The MEL 80 Excimer Laser System will be evaluated for its ability to create accurate and stable hyperopic refractive correction results.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
Time frame: Point of stability
Time frame: Point of stability
Time frame: Point of stability
Time frame: Point of stability
Time frame: Point of stability
Time frame: Point of stability
Time frame: Point of stability
Time frame: Postoperative visits
Time frame: Postoperative visits 3, 6, 9, 12, 18 and 24 months
Time frame: Postoperative visits
Time frame: Preoperative and Postoperative visits 3, 6, 9, 12, 18 and 24 months
Carl Zeiss Meditec, Inc.
Industry
A Prospective, Randomized, Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of ≤ +6.0 D Of Hyperopia With Or Without Astigmatism Of +0.50 D To +3.50 D And MRSE ≤ +6.50 D
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06758076
Eye Diseases, Hyperopia
Manchester, United Kingdom
View Trial DetailsNCT06869044
Eye Diseases, Hyperopia
Berkeley, California, United States
View Trial DetailsNCT07276347
Eye Diseases, Hyperopia
Bloomington, Indiana, United States
View Trial DetailsNCT06873048
Astigmatism, Eye Diseases
Waterloo, Ontario, Canada
View Trial Details